Severe Esophagitis and Gastritis from Nivolumab Therapy.

Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, however, upper gastrointestinal events are rarely reported. We present a case of nivolumab-associated esophagitis and gastritis that has yet to be reported in the published literature.